
FDA-Approved Migraine Drug Reverses Circadian Disruption in Mice via Predicted CRY1 Binding
An FDA-approved migraine medication may hold the key to repairing broken circadian clocks. A computational screening study published this week in Molecular Diversity identifies dihydroergotamine (DHE) as a promising candidate for reversing the physiological damage caused by circadian disruption. In sleep-deprived mice, the drug restored weight stability, rescued recognition memory, and normalized sleep architecture through […]










